Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

ions.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus, or HPV. The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include clinical development and other projections as well as statements regarding the Company's future plans, objectives, performance, operating expenses, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: evaluation of the remaining cohort by the end of the second quarter; the beginning of our Phase 2 clinical program; and continued advancement of HspE7 for HPV-related diseases.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by su
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)... 2014 iLab Solutions announced the results ... which focuses on core facility operations, growth and ... face today. , In its 4th year running, a ... is the year-over-year decrease in the percentage of revenue ... be feeling the constraints of this trend. When asked, ...
(Date:9/30/2014)... CT (PRWEB) September 30, 2014 ... of scientific research products, recently opened an online ... comprehensive cell culture product lines developed and manufactured ... its online store include Biological Industries’ Nutristem® serum-free, ... and human embryonic stem cell (hESC) culture. ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2
... Arginine vasopressin (AVP) receptor antagonist now approved in single-use ... ... 22 Astellas Pharma US, Inc. today,announced that the U.S. ... of Vaprisol: Vaprisol(R) (conivaptan hydrochloride,injection) Premixed in 5% Dextrose. Discovered ...
... November 18, 2008, WITTEN, Germany, October 22 ... fiscal year,ended June 30, 2008, on October 21. According ... SEC the company yielded sales of its cosmetics and ... a decrease,of 44% as compared with sales revenues of ...
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical ... that it will present at three upcoming investor conferences:, ... the Hyatt Regency in La,Jolla, Calif. on Monday, October ... -- Oppenheimer,s 19th Annual Healthcare Conference to be ...
Cached Biology Technology:FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses 2Halozyme Therapeutics to Present at Upcoming Investor Conferences 2
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/30/2014)... ARLINGTON HEIGHTS, Ill. (September 30, 2014) People who ... they can do to control their asthma besides properly ... to a new article in the Annals of ... the American College of Allergy, Asthma and Immunology (ACAAI), ... by examining their lifestyle. The woman described in the ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2
... The U.S. Food and Drug Administration (FDA) granted market ... bionic eye to be approved for patients in the ... with support from the National Science Foundation (NSF). ... transmits images from a small, eye-glass-mounted camera wirelessly to ...
... be an early step toward new treatments for people with ... probiotic supplement can help male mice produce healthier bones. ... researchers report in the Journal of Cellular Physiology . ... bone loss, though it,s unclear exactly why," said lead author ...
... that cold-blooded animals, such as worms, flies and fish ... known exactly why. , Researchers at the University of ... that promotes longevity of roundworms in cold environmentsand this ... , "This raises the intriguing possibility that exposure to ...
Cached Biology News:Artificial retina receives FDA approval 2Artificial retina receives FDA approval 3Artificial retina receives FDA approval 4Artificial retina receives FDA approval 5Building healthy bones takes guts 2Stay cool and live longer? 2
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids 926-941 ... immunoaffinity purified Quality Assurance ... lysates from HeLa cells. Stability ...
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
MarrowMAX Bone Marrow Medium...
Replacement Parts for Electrophoresis Apparatus...
Biology Products: